Therapeutic apheresis in kidney diseases: an updated review

Ren Fail. 2022 Dec;44(1):842-857. doi: 10.1080/0886022X.2022.2073892.

Abstract

Besides conventional medical therapies, therapeutic apheresis has become an important adjunctive or alternative therapeutic option to immunosuppressive agents for primary or secondary kidney diseases and kidney transplantation. The available therapeutic apheresis techniques used in kidney diseases, including plasma exchange, double-filtration plasmapheresis, immunoadsorption, and low-density lipoprotein apheresis. Plasma exchange is still the leading extracorporeal therapy. Recently, growing evidence supports the potential benefits of double-filtration plasmapheresis and immunoadsorption for more specific and effective clearance of pathogenic antibodies with fewer side effects. However, more randomized controlled trials are still needed. Low-density lipoprotein apheresis is also an important supplementary therapy used in patients with recurrent focal segmental glomerulosclerosis. This review collects the latest evidence from recent studies, focuses on the specific advantages and disadvantages of these techniques, and compares the discrepancy among them to determine the optimal therapeutic regimens for certain kidney diseases.

Keywords: Therapeutic apheresis; double-filtration plasmapheresis; immunoadsorption; kidney transplantation; plasma exchange.

Publication types

  • Review

MeSH terms

  • Blood Component Removal* / methods
  • Humans
  • Kidney Diseases* / etiology
  • Kidney Diseases* / therapy
  • Kidney Transplantation*
  • Lipoproteins, LDL
  • Plasmapheresis

Substances

  • Lipoproteins, LDL

Grants and funding

This work was supported by the National Natural Science Foundation of China under Grants [No. 81974097, No. 81400720, No. 81961138007, No. 81974096, No. 81770711].